What is Flow Neuroscience?
Flow Neuroscience is a Swedish medical device company focused on developing and commercializing a transcranial direct current stimulation (tDCS) device paired with a behavioral therapy application designed to treat depression. The company's approach integrates hardware and software to provide a non-invasive therapeutic option for individuals suffering from depressive disorders. By combining tDCS technology with a user-friendly app, Flow Neuroscience aims to make advanced mental health treatments more accessible and effective.
How much funding has Flow Neuroscience raised?
Flow Neuroscience has raised a total of $11.9M across 3 funding rounds:
Angel/Seed
$1.1M
Other Financing Round
$1.5M
Series A
$9.3M
Angel/Seed (2018): $1.1M with participation from Khosla Ventures and SOSV
Other Financing Round (2019): $1.5M led by Khosla Ventures
Series A (2021): $9.3M supported by Swiss Health Ventures, Khosla Ventures, and Zühlke Ventures
Key Investors in Flow Neuroscience
Khosla Ventures
Khosla Ventures is a prominent venture capital firm known for backing transformative technologies across various sectors, including health and AI. Their investment in Flow Neuroscience suggests a belief in the company's innovative approach to mental health treatment.
Khosla Ventures
Khosla Ventures, a venture capital firm with a broad investment thesis, has participated in Flow Neuroscience's funding rounds. Their continued backing indicates a strategic interest in the company's growth and market potential.
Swiss Health Ventures
Swiss Health Ventures is an investor focused on the healthcare sector. Their participation in Flow Neuroscience's Series A round highlights the company's alignment with strategic health investment opportunities.
What's next for Flow Neuroscience?
The recent major strategic investment signals a pivotal growth phase for Flow Neuroscience, likely enabling the company to scale its operations, expand its market reach, and further develop its product offerings. This capital infusion is expected to accelerate the adoption of its depression treatment device and app, potentially leading to broader clinical integration and enhanced patient access. The company's focus on innovation in mental health technology positions it for continued advancement in the competitive medtech landscape.
See full Flow Neuroscience company page
